- Home
- ROIV vs J Comparison
ROIV vs J Comparison
Compare ROIV & J Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | J |
|---|---|---|
| Founded | 2014 | 1947 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 17.5B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | J |
|---|---|---|
| Price | $28.58 | $136.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $27.56 | ★ $156.60 |
| AVG Volume (30 Days) | ★ 6.3M | 941.0K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.06% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.12 |
| Revenue | $29,053,000.00 | ★ $14,984,646,000.00 |
| Revenue This Year | N/A | $13.41 |
| Revenue Next Year | $385.85 | N/A |
| P/E Ratio | ★ N/A | $121.54 |
| Revenue Growth | N/A | ★ 49.51 |
| 52 Week Low | $8.73 | $106.23 |
| 52 Week High | $30.03 | $168.44 |
Technical Indicators
Market Signals| Indicator | ROIV | J |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 48.08 |
| Support Level | $20.46 | $131.96 |
| Resistance Level | N/A | $143.31 |
| Average True Range (ATR) | 0.95 | 4.41 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 66.80 | 49.69 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About J Jacobs Solutions Inc.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $12 billion in revenue in fiscal 2025.